OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Tarantino on Advances Allowing for Tailored Treatment in HER2+ Breast Cancer

September 16th 2024

Paolo Tarantino, MD, discusses advancements that may lead to more tailored treatment approaches in early-stage HER2+ breast cancer.

Dr Banerjee on the Benefit of Bispecific Antibody Dose Reduction in Multiple Myeloma

September 16th 2024

Rahul Banerjee, MD, FACP, discusses clinical benefits derived when reducing the dosing of bispecific antibodies in the management of multiple myeloma.

Dr Friedlander on AEs Associated With Enfortumab Vedotin in Bladder Cancer

September 16th 2024

Terence W. Friedlander, MD, discusses adverse effects that are associated with standard enfortumab vedotin in bladder cancer.

Dr Yuan on the Investigation of Adjuvant CDK4/6 Inhibition in Breast Cancer

September 16th 2024

Yuan Yuan, MD, PhD, discusses key research evaluating adjuvant CDK4/6 inhibition in breast cancer.

Dr Choueiri on Lessons Learned from the TiNivo-2 Study in Metastatic RCC

September 15th 2024

Toni Choueiri, MD, discusses findings with tivozanib plus nivolumab in metastatic RCC after progression on an immune checkpoint inhibitor.

Dr Secord on Mirvetuximab Soravtansine in Platinum-Sensitive, FRα-High Ovarian Cancer

September 15th 2024

Angeles A. Secord, MD, MHSc, discusses the PICCOLO trial of mirvetuximab soravtansine in recurrent, platinum-sensitive, FRα-high ovarian cancer.

Dr Lin on the Efficacy of T-DXd in HER2+ Advanced Breast Cancer With CNS Metastases

September 14th 2024

Nancy U. Lin, MD, discusses the DESTINY-Breast12 trial of T-DXd in patients with HER2-positive metastatic breast cancer with or without brain metastases.

Dr Girard on Nivolumab Plus Relatlimab and Chemotherapy in Stage IV or Recurrent NSCLC

September 14th 2024

Nicolas Girard, MD, discusses the RELATIVITY-104 trial of nivolumab plus relatlimab and chemotherapy in previously untreated stage IV or recurrent NSCLC.

Dr Wilky on a Study of Botensilimab Plus Balstilimab in Refractory Metastatic Sarcoma

September 13th 2024

Breelyn Wilky, MD, discusses updated findings from a phase 1 study investigating botensilimab plus balstilimab in refractory metastatic sarcoma.

Dr Jonasch on the Preliminary Efficacy of NKT-2152 in Advanced ccRCC

September 13th 2024

Eric Jonasch, MD, discusses preliminary findings from a trial investigating NKT-2152 in previously treated advanced clear cell renal cell carcinoma.

Cannavale on the Importance of Assessing Comorbidities and Remission Rates in Ovarian Cancer

September 13th 2024

Kimberly Cannavale, MPH, discusses the clinical implications of a study on the impact of pre-existing comorbidities on remission rates in ovarian cancer.

Dr Banerjee on the Impact of Dose Modification Studies in Multiple Myeloma

September 13th 2024

Rahul Banerjee, MD, FACP, discusses the clinical impact of dose modification studies on the treatment of patients with multiple myeloma.

Dr Nowakowski on Unmet Needs to be Addressed in R/R Follicular Lymphoma

September 13th 2024

Grzegorz S. Nowakowski, MD, discusses unmet needs that remain to be addressed in patients with relapsed/refractory follicular lymphoma.

Dr Price on the Potential Role for HPV-Targeted Immunotherapy Vaccines in HPV+ HNSCC

September 12th 2024

Katharine A. Price, MD, discusses the potential role for injectable HPV-targeted immunotherapy vaccines in HPV16-positive head and neck squamous cell carcinoma.

Dr Kim on the Safety of NT-17 Plus Pembrolizumab in Pretreated CRC and PDAC

September 11th 2024

Richard Kim, MD, discusses the safety of NT-17 and next steps for its evaluation in pretreated microsatellite stable CRC and PDAC.

Dr Danilov on the Current and Potential Use of Pirtobrutinib in CLL

September 11th 2024

Alexey Danilov, MD, PhD, discusses the utility of pirtobrutinib in patients with chronic lymphocytic leukemia.

Dr Danilov on Ongoing MCL Clinical Trials

September 11th 2024

Alexey Danilov, MD, PhD, discusses ongoing investigations taking place to improve the treatment of patients with mantle cell lymphoma.

Dr Eads on the Rationale for ECOG-ACRIN EA2174 in Esophageal/GEJ Adenocarcinoma

September 11th 2024

Jennifer R. Eads, MD, discusses the evaluation of the addition of nivolumab to neoadjuvant chemotherapy and radiation in esophageal/GEJ adenocarcinoma.

Dr Braun on the Role of Biomarkers in Guiding Adjuvant Treatment for RCC

September 11th 2024

David A. Braun, MD, PhD, discusses the role of biomarkers in guiding adjuvant treatment strategies for renal cell carcinoma.

Cannavale on the Effect of Comorbidity on Remission Rates in Epithelial Ovarian Cancer

September 11th 2024

Kimberly Cannavale, MPH, discusses the rationale for investigating the effect of pre-existing comorbidities on remission rates in ovarian cancer.